CN113613650B - 治疗贫血的毒蕈碱乙酰胆碱受体亚型4拮抗剂 - Google Patents
治疗贫血的毒蕈碱乙酰胆碱受体亚型4拮抗剂 Download PDFInfo
- Publication number
- CN113613650B CN113613650B CN202080024089.9A CN202080024089A CN113613650B CN 113613650 B CN113613650 B CN 113613650B CN 202080024089 A CN202080024089 A CN 202080024089A CN 113613650 B CN113613650 B CN 113613650B
- Authority
- CN
- China
- Prior art keywords
- formula
- compound
- bfu
- cells
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962823214P | 2019-03-25 | 2019-03-25 | |
| US62/823,214 | 2019-03-25 | ||
| PCT/US2020/023989 WO2020198054A1 (en) | 2019-03-25 | 2020-03-20 | Muscarinic acetylcholine receptor subtype 4 antagonists in the treatment of anemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113613650A CN113613650A (zh) | 2021-11-05 |
| CN113613650B true CN113613650B (zh) | 2024-12-10 |
Family
ID=72608578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080024089.9A Active CN113613650B (zh) | 2019-03-25 | 2020-03-20 | 治疗贫血的毒蕈碱乙酰胆碱受体亚型4拮抗剂 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12497411B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3946321A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7558187B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102914803B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN113613650B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020247812B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021019189A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3132381A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL286617A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021011588A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202109857UA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020198054A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113613650B (zh) | 2019-03-25 | 2024-12-10 | 冷泉港实验室 | 治疗贫血的毒蕈碱乙酰胆碱受体亚型4拮抗剂 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019010491A1 (en) * | 2017-07-07 | 2019-01-10 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | COMBINATIONS OF MEDICINES FOR THE PROTECTION AGAINST THE DEATH OF NEURONAL CELLS |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3649626A (en) * | 1970-04-27 | 1972-03-14 | Warner Lambert Co | Fused ring systems containing (1 3)oxazine |
| DK1282625T3 (da) * | 2000-05-09 | 2004-11-15 | Warner Lambert Co | Anvendelsen af benzoxaziner i behandlingen af Parkinsons sygdom |
| CA2357306A1 (en) | 2000-09-22 | 2002-03-22 | Warner-Lambert Company | Fused ring system containing indole as m4 selective aza-anthracene muscarinic receptor antagonists |
| US8329689B2 (en) * | 2006-05-23 | 2012-12-11 | Alexandre Vasilievich Ivachtchenko | Substituted indoles and a method for the production and use thereof |
| US20130059783A1 (en) * | 2010-03-12 | 2013-03-07 | Johan Flygare | Compositions and methods for expanding bfu-e cells |
| EP3490542A4 (en) | 2016-07-26 | 2020-07-08 | Flagship Pioneering Innovations V, Inc. | NEUROMODULATION COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATION OF AN ANTI-CANCER RESPONSE |
| CN113613650B (zh) | 2019-03-25 | 2024-12-10 | 冷泉港实验室 | 治疗贫血的毒蕈碱乙酰胆碱受体亚型4拮抗剂 |
-
2020
- 2020-03-20 CN CN202080024089.9A patent/CN113613650B/zh active Active
- 2020-03-20 JP JP2021553300A patent/JP7558187B2/ja active Active
- 2020-03-20 AU AU2020247812A patent/AU2020247812B2/en active Active
- 2020-03-20 CA CA3132381A patent/CA3132381A1/en active Pending
- 2020-03-20 KR KR1020217029823A patent/KR102914803B1/ko active Active
- 2020-03-20 SG SG11202109857U patent/SG11202109857UA/en unknown
- 2020-03-20 EP EP20776829.2A patent/EP3946321A4/en active Pending
- 2020-03-20 WO PCT/US2020/023989 patent/WO2020198054A1/en not_active Ceased
- 2020-03-20 MX MX2021011588A patent/MX2021011588A/es unknown
- 2020-03-20 BR BR112021019189A patent/BR112021019189A2/pt unknown
- 2020-03-20 US US17/442,926 patent/US12497411B2/en active Active
-
2021
- 2021-09-23 IL IL286617A patent/IL286617A/en unknown
-
2024
- 2024-05-20 JP JP2024081788A patent/JP2024102364A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019010491A1 (en) * | 2017-07-07 | 2019-01-10 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | COMBINATIONS OF MEDICINES FOR THE PROTECTION AGAINST THE DEATH OF NEURONAL CELLS |
Non-Patent Citations (3)
| Title |
|---|
| Analogs of M4 selective synthetic muscarinic receptor antagonists: synthesis, binding and pharmacokinetic properties;Boehme Thomas M等;《 Medicinal chemistry research》;第11卷(第8期);第423-433页 * |
| IDENTIFICATION AND CHARACTERIZATION OF m4 SELECTIVE MUSCARINIC ANTAGONISTS;Corinne E. Augelli-Szafran等;《Bioorganic & Medicinal Chemistry Letters》;第8卷(第15期);第1991-1996页 * |
| Synthesis and Pharmacology of Benzoxazines as Highly Selective Antagonists at M4 Muscarinic Receptors;Thomas M. Bohme等;《J. Med. Chem.》;第45卷(第14期);第3049-3102页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202109857UA (en) | 2021-10-28 |
| IL286617A (en) | 2021-10-31 |
| KR102914803B1 (ko) | 2026-01-20 |
| CA3132381A1 (en) | 2020-10-01 |
| EP3946321A4 (en) | 2023-03-08 |
| JP2024102364A (ja) | 2024-07-30 |
| JP2022525293A (ja) | 2022-05-12 |
| MX2021011588A (es) | 2021-12-15 |
| AU2020247812B2 (en) | 2025-09-11 |
| BR112021019189A2 (pt) | 2021-11-30 |
| KR20210144697A (ko) | 2021-11-30 |
| AU2020247812A1 (en) | 2021-09-30 |
| JP7558187B2 (ja) | 2024-09-30 |
| US20220185821A1 (en) | 2022-06-16 |
| CN113613650A (zh) | 2021-11-05 |
| WO2020198054A1 (en) | 2020-10-01 |
| EP3946321A1 (en) | 2022-02-09 |
| US12497411B2 (en) | 2025-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6970802B2 (ja) | 二官能性分子によって標的化タンパク質分解を誘導する方法 | |
| CN114728938B (zh) | 作为prmt5抑制剂的四氢异喹啉螺环化合物 | |
| KR20240055788A (ko) | 신규한 ras 억제제 | |
| WO2020027083A1 (ja) | キナゾリン化合物を有効成分とする医薬組成物 | |
| TW201840563A (zh) | 治療b型肝炎病毒感染的化合物 | |
| JP2011526295A (ja) | ５員および６員複素環化合物 | |
| RS54038B1 (sr) | Imidazo[4,5-c]hinolini kao inhibitori dnk-pk | |
| JP2022522942A (ja) | 有機化合物 | |
| US20230055237A1 (en) | Compounds and methods for the treatment of cystic fibrosis | |
| TW201722952A (zh) | Ｃｇｒｐ受體拮抗劑 | |
| US20240252658A1 (en) | Bifunctional protac-type compounds targeting pxr, method for preparing same and therapeutic use thereof | |
| TW202204354A (zh) | 用於ｃｓｋ調節之化合物及方法以及其說明 | |
| CN113613650B (zh) | 治疗贫血的毒蕈碱乙酰胆碱受体亚型4拮抗剂 | |
| CN117916234A (zh) | 作为tyk2/jak1假激酶结构域抑制剂的化合物及合成和使用方法 | |
| EP4076466B1 (en) | Modulators of cullin 3 adaptor kbtbd4 as anti-cancer compounds | |
| EP3743422B1 (en) | Crystalline forms of the cxcr7 receptor antagonist (3s,4s)-1-cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide | |
| US20240391880A1 (en) | KCa3.1 INHIBITORS FOR PODOCYTE PROTECTION | |
| JP2022507559A (ja) | Ａｍ２受容体阻害剤としての複素環スピロ化合物 | |
| JP2020525476A (ja) | インドールアミン２，３−ジオキシゲナーゼのモジュレーター | |
| WO2025255442A1 (en) | Trim21-targeted compounds and uses thereof | |
| CN116162093A (zh) | 一种tyk2抑制剂化合物及其用途 | |
| WO2025101588A1 (en) | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders | |
| WO2025230871A1 (en) | Compounds, compositions, methods of use, and methods for preparing compounds | |
| EP4604961A1 (en) | Compounds for the treatment of cancer | |
| US20200361902A1 (en) | Crystal form i of a 5-aminopyrazole carboxamide compound as btk inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |